InvestorsHub Logo
Followers 242
Posts 12310
Boards Moderated 0
Alias Born 08/14/2003

Re: vinmantoo post# 1067

Saturday, 12/02/2023 11:47:22 PM

Saturday, December 02, 2023 11:47:22 PM

Post# of 1106
Vinmantoo, we're in much the same position, but I'm far from thrilled about the price IMGN is taking. I understand that ABBV's revenue estimate for Elahere alone is $2 billion a year, that alone should justify a $20 billion buyout with a P/E of only 10 and it could very well be 20 or more over the years. In the clinic they're already getting what should be the second generation of Elahere, an even more effective drug which should have a broader label. Their drug, Pivek, for BPDCN ought to be a sure approval for it, whether it's benefit in leukemia is that great, or not. It may, or may not be a blockbuster, depending on the outcome with leukemia, but it's a miracle worker for BPDCN.

They still have their technology in a number of other partnerships where with approval they could earn substantial milestone and royalty payments, I believe all of those will remain in force, only it will be found money for ABBV, not IMGN.

I may be one of the few who've been in this essentially from it's beginning, I've always felt in time it would have a big payday. I believe this is a moderate one, not one that's really big to celebrate. I hope that one or more of the Institutions see it as I do, if they do and make their opposition clear, I believe others will support a no vote and it will either achieve a better offer from ABBV, or a much higher price if the company operates independently for another year or two. At least in a year or two a much greater knowledge of our pipeline will be known, if it's positive we'll be worth a lot more, if it's not, Elahere sales will still be higher, so we'll be worth more than we are today.

My position in NWBO is already quite large, and if it's up in the next few months, as I expect, it could exceed IMGN, so I don't know that I want to add more to it, though I believe their vaccine could become a part of the SOC in many solid cancers in the next several years with trials proving the vaccine is truly tumor agnostic. I'm considering a position in AVXL, their Alzheimer's drug has a good chance of getting European approval sometime next year, if it does, I believe the FDA and others will follow. I'm certainly happy to learn of other leading edge companies to consider.

Gary
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IMGN News